clinical trial · NCT03350451
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
PH1Primary HyperoxaluriaRNAi TherapeuticsiRNAAGTLumasiran
brief summary
The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in participants with Primary Hyperoxaluria Type 1.
started
Apr 4, 2018
primary completion
Feb 7, 2023
completion
Feb 7, 2023
last updated
Apr 25, 2024
official title
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol